What 2026’s Alzheimer’s News Means for Families: Blood Tests, New Drugs, and What to Ask
If you’ve cared for a parent with dementia, you’ve probably seen the headlines: a blood test for Alzheimer’s, new drugs that “slow the disease.” After a diagnosis, those words can land hard — as hope, as panic, as one more thing you’re supposed to understand by tonight.
Here’s a calm, sourced summary of what actually changed in 2025–2026, written plainly. We’re reporting what leading authorities have announced — we’re an editorial team, not clinicians — so the goal here is to help you understand the news and turn it into the right questions for your parent’s care team, not to tell you what to do medically.
Important — please read. This page is journalism-style orientation, not medical advice and not treatment guidance. Nothing here says any treatment or test is right for your parent. Every decision about diagnosis, testing, eligibility, and treatment belongs entirely to your parent’s care team. We’ve sourced each claim so you can take it to that conversation.
Why families are hearing about this now
Two developments — new blood-based diagnostic tests and FDA-approved treatments for early Alzheimer’s — moved from research into clinics between 2023 and 2026, which is why they’re suddenly in the news and in doctors’ offices (Alzheimer’s Association). Below is what each one is, in plain language — and, just as important, what it isn’t.
1. New blood tests for Alzheimer’s
For the first time, blood tests have been FDA-cleared to aid in the diagnosis of Alzheimer’s — helping clinicians assess whether Alzheimer’s-related amyloid may be present, a question that until now usually relied on a PET brain scan or a spinal tap. Two reached the clinic:
- In May 2025, the US FDA cleared the first such blood test, Fujirebio’s Lumipulse G pTau 217/β-Amyloid ratio test, to help clinicians confirm whether Alzheimer’s-related amyloid is present (Johns Hopkins Medicine).
- In October 2025, the FDA cleared Roche’s Elecsys pTau181 plasma test for use in primary care to help rule out Alzheimer’s-related amyloid in people with cognitive symptoms (Roche).
What this means, plainly: as those authorities describe them, these tests can give a clinician another, less invasive input when evaluating possible Alzheimer’s. What it does not mean: the Alzheimer’s Association is explicit that there is no single, standalone test for Alzheimer’s today — a blood test is one input used within a full clinical assessment, not a verdict on its own, and not something to self-order (Alzheimer’s Association). A positive result is not a death sentence; a negative one is not a guarantee. Whether such a test is appropriate for your parent is a question for the care team (Alzheimer’s Association).
2. New disease-modifying drugs for early Alzheimer’s
For most of history, Alzheimer’s drugs could only ease symptoms. Two newer “anti-amyloid” treatments are the first approved to target the underlying disease process — and the key word in every official description is early:
- Lecanemab (Leqembi) received traditional FDA approval in July 2023 for Alzheimer’s disease, with treatment started in the mild cognitive impairment or mild-dementia stage; trials found it slowed the rate of decline versus placebo. A subcutaneous maintenance form was FDA-approved in early 2026 (Alzheimer’s Association).
- Donanemab (Kisunla) received FDA approval in July 2024 for early symptomatic Alzheimer’s — mild cognitive impairment or mild dementia stage, with confirmed amyloid — also targeting amyloid plaques (Alzheimer’s Association).
What this means, plainly: the Alzheimer’s Association describes these as treatments aimed at the biology of Alzheimer’s — targeting amyloid — rather than only its symptoms. What it does not mean: they are not cures — the trial benefit was a slowing of decline, not a reversal. They are approved only for the early stage with confirmed amyloid, carry serious potential side effects that require monitoring (called ARIA), and access and coverage remain real hurdles. Whether any of this fits your parent is strictly a care-team decision, ideally with a specialist (Alzheimer’s Association).
3. A Medicare program that may help caregivers directly
In July 2024, Medicare launched the GUIDE Model — an eight-year pilot offering coordinated dementia care, a 24/7 support line, caregiver training, and up to $2,500 a year toward respite services for eligible participants. By mid-2025, 330+ organizations were participating (CMS; AARP).
Why this one is worth a direct question: unlike the tests and drugs, this is a care model that can include direct support for you, the caregiver. It’s a pilot, not a universal entitlement, so availability depends on whether your parent’s practice participates — which is exactly the kind of thing worth asking the care team: “Are you a GUIDE Model participant, and would we be eligible?”
Turning the news into questions (the Care90 part)
You don’t have to evaluate any of this alone — and you shouldn’t. The useful move is to convert a headline into a question for the people who can actually answer it. Bring these written:
- “Given my parent’s stage, are any of the newer diagnostic tests relevant to us?”
- “Are the newer anti-amyloid treatments something we should even be discussing, or is my parent outside the approved early-stage window?”
- “If they could be relevant, what are the risks, the monitoring, and the access realities?”
- “Are you part of the Medicare GUIDE Model, and could we get the caregiver support and respite benefit?”
→ Keep these with your other questions in What to Ask at Your Parent’s First Dementia Appointment, and file the answers in your caregiver binder.
FAQ
Is there now a blood test that diagnoses Alzheimer’s? The FDA has cleared blood tests (2025) that aid in diagnosis — helping clinicians detect or rule out Alzheimer’s-related amyloid. But the Alzheimer’s Association is clear there is no single, standalone test for Alzheimer’s: these are used within a full clinical assessment and ordered by a doctor, never a self-ordered verdict. Whether one is appropriate for your parent is a care-team decision (Alzheimer’s Association).
Do the new drugs cure Alzheimer’s? No. According to the Alzheimer’s Association, lecanemab and donanemab slow decline in early-stage Alzheimer’s for eligible people; they are not cures and carry side effects requiring monitoring (Alzheimer’s Association).
My parent is in a later stage — do these apply? The approvals are for the early stage with confirmed amyloid. The right people to confirm what applies to your parent are their care team. Whatever the stage, getting organized still helps: My Parent Was Just Diagnosed. What Do I Do First?
Sources
| Claim | Source | Accessed |
|---|---|---|
| Blood test FDA clearances (Lumipulse G, May 2025; Elecsys pTau181, Oct 2025) | Johns Hopkins Medicine · Roche | 2026-06-13 |
| No single standalone test; blood tests aid diagnosis / rule out amyloid pathology | Alzheimer’s Association — FDA clearance to rule out amyloid | 2026-06-13 |
| Lecanemab (Leqembi) approval July 2023, subcutaneous 2026; slows decline; early-stage only; ARIA | Alzheimer’s Association — Lecanemab | 2026-06-13 |
| Donanemab (Kisunla) FDA approval July 2024, early symptomatic only | Alzheimer’s Association — Donanemab | 2026-06-13 |
| Medicare GUIDE Model: July 2024 launch, 330+ orgs, $2,500/yr respite | CMS · AARP | 2026-06-13 |
By Care90 Editorial — not doctors, clinicians, or researchers. We summarize publicly reported developments from named authorities so families can discuss them with the right professionals. Care90 builds calm organizing systems for families after a parent’s diagnosis. Always consult your parent’s medical team for clinical advice.
News changes fast. The fundamentals — get organized, ask better questions — don’t. My Parent Was Just Diagnosed. What Do I Do First? — a 90-day system to move forward with calm and clarity. Get it on Amazon — $9.99 Kindle / $19.99 Paperback →